BTIG maintains Mereo BioPharma Group at Buy, keeps price target at $1TradingView·Nov 10, 2026 at 08:27 AMMREO-5.45%
Capital Rotates to Niche Commodities and Vertical Tech Amid Asset Sales and AI PushGlobal Report·Sep 22, 2026 at 10:14 AMARW-6.10%GORO+2.10%
MREO: Late-stage rare disease programs near regulatory milestones, with major updates due in the next quarterQuartr·Sep 10, 2026 at 04:20 PMMREO-5.45%
Mereo BioPharma CEO joins Cantor Global Healthcare Conference fireside chatPUBT·Sep 7, 2026 at 09:28 AMMREO-5.45%
Mereo BioPharma Group's (MREO) "Underweight" Rating Reiterated at JPMorgan Chase & Co.Market Beat·Aug 19, 2026 at 12:42 PMMREO-5.45%
Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestatPharmaceutical Technology·Aug 12, 2026 at 09:14 AMMREO-5.45%